BioMarin Pharmaceutical Inc. BMRN
56.67 USD -1.66 (-2.84%)
Nov 12, 2026, 3:52 PM EST
56.21 Day range 58.68
49.26 52-week range 70.98
- YTD
- -4.64%
- 1 year
- +2.44%
News
marketbeat.com BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline BioMarin Pharmaceutical NASDAQ: BMRN is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a…
seekingalpha.com BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
defenseworld.net Bfsg LLC Buys 17,538 Shares of BioMarin Pharmaceutical Inc. $BMRN Bfsg LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor…
benzinga.com JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86 JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $87 to $86.
benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $122 to $119.
benzinga.com Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94 Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.- benzinga.com HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
benzinga.com RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60 RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $62 to $60.
benzinga.com Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66 Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $70 to $66.
benzinga.com Biomarin Pharmaceutical Q3 2026 Earnings Call Transcript Biomarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Biomarin Pharmaceutical Q3 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.025B Miss $1.026B Estimate Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.12 by 91.67 percent. This is a 91.67 percent increase over…
benzinga.com BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 Est; Lowers FY2026 Sales Guidance from $3.875B-$3.925B to $3.800B-$3.900B vs $3.918B Est BioMarin Pharmaceutical (NASDAQ:BMRN) lowers FY2026 Adj EPS guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 analyst estimate. Lowers FY2026 sales outlook from $3.875 billion-$3.925 billion to…- benzinga.com BioMarin Pharmaceutical Enters License Agreement With GC Biopharma And Hanmi Pharm To Develop And Commercialize Its HM15421/GC1134A Investigational Long-Acting Enzyme Replacement Therapy For Fabry Disease; Company To Pay $70M Up Front, With Partners Eligible For Up To $405M In Milestones HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential…
benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.- benzinga.com Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
- benzinga.com Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114 Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.
- benzinga.com BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis Showcases Impact Of VOXZOGO In Foramen Magnum And Craniocervical Junction Growth The data include encouraging new imaging results from a post-hoc analysis of a randomized, double-blind, placebo-controlled trial evaluating the effect of VOXZOGO on the growth of the foramen magnum…
benzinga.com BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease…- benzinga.com BioMarin Pharmaceutical Decides To Discontinue Development Of VOXZOGO For Children With Noonan Syndrome On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. BioMarin made this decision after…
- benzinga.com HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
benzinga.com QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial failure.
benzinga.com Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90 Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $88 to $90.- benzinga.com Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105 Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $105.
benzinga.com Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.The Dow traded down 0.64% to 53,219.55 while the NASDAQ dipped 0.40% to 26,296.20.…- benzinga.com HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $59 to $60.
benzinga.com Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc.…
benzinga.com Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting BioMarin significant royalty payments.- benzinga.com Reported Earlier, BioMarin Settles Global Yuviwel Dispute, Secures Up To 20% Sales Royalty BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including…
benzinga.com This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.
benzinga.com This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.- benzinga.com BMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98 BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $98.
benzinga.com BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.- benzinga.com HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $59 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $60 to $59.
- benzinga.com BioMarin Pharmaceutical Signs Agreement To Acquire Alesta Therapeutics For $275M BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.…
- benzinga.com Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $88 Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $82 to $88.
- benzinga.com Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $111 Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $105 to $111.
- benzinga.com Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $114 Canaccord Genuity analyst Whitney Ijem maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $111 to $114.
- benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $124 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $119 to $124.
- benzinga.com Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Raises Price Target to $97 Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $95 to $97.
- benzinga.com HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $50 to $60.
- benzinga.com BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.825B-$3.925B to $3.875B-$3.925B vs $3.875B Est BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to…
- benzinga.com Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.69 by 73.91 percent. This is a 16.67 percent decrease over…
- benzinga.com Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76 Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $75 to $76.
- benzinga.com MioMarin Pharmaceuticals Receives FDA Supplemental New Drug Application Approval For Vosoritide To Treat Pediatric Achondroplasia The sNDA submission was supported by substantial long-term safety and efficacy data from three ongoing studies (111-205, 111-208 and 111-302), including clinically meaningful results in growth and…
- benzinga.com RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $62 RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $66 to $62.
- benzinga.com BioMarin Pharmaceutical Presented New Data From Phase 2 Three-Year Extension Study Of VOXZOGO In 13 Children With Hypochondroplasia That Demonstrated Sustained Improvements In Annualized Growth Velocity And Height Standard Deviation Score BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced new data from studies of VOXZOGO® (vosoritide) in children with hypochondroplasia and the investigational medicine BMN 333 in achondroplasia were…
benzinga.com BioMarin Reveals Dwarfism Study Data, Stock Soars BioMarin stock climbed after Phase 3 VOXZOGO data showed significant growth improvements in children with hypochondroplasia.- benzinga.com B of A Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80 B of A Securities analyst Jason Zemansky maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $85 to $80.
- benzinga.com Citigroup Initiates Coverage On BioMarin Pharmaceutical with Buy Rating, Announces Price Target of $75 Citigroup analyst Eric Joseph initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy rating and announces Price Target of $75.
- benzinga.com HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $50 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $55 to $50.